Neuroprotective effects of progesterone in chronic experimental autoimmune encephalomyelitis. 2012

S Giatti, and D Caruso, and M Boraso, and F Abbiati, and E Ballarini, and D Calabrese, and M Pesaresi, and R Rigolio, and M Santos-Galindo, and B Viviani, and G Cavaletti, and L M Garcia-Segura, and R C Melcangi
Department of Endocrinology, Pathophysiology and Applied Biology, Center of Excellence on Neurodegenerative Diseases, Università degli Studi di Milano, Milano, Italy.

Observations so far obtained in experimental autoimmune encephalomyelitis (EAE) have revealed the promising neuroprotective effects exerted by progesterone (PROG). The findings suggest that this neuroactive steroid may potentially represent a therapeutic tool for multiple sclerosis (MS). However, up to now, the efficacy of PROG has been only tested in the acute phase of the disease, whereas it is well known that MS expresses different features depending on the phase of the disease. Accordingly, we have evaluated the effect of PROG treatment in EAE induced in Dark Agouti rats (i.e. an experimental model showing a protracted relapsing EAE). Data obtained 45 days after EAE induction show that PROG treatment exerts a beneficial effect on clinical score, confirming surrogate parameters of spinal cord damage in chronic EAE (i.e. reactive microglia, cytokine levels, activity of the Na(+) ,K(+) -ATPase pump and myelin basic protein expression). An increase of the levels of dihydroprogesterone and isopregnanolone (i.e. two PROG metabolites) was also observed in the spinal cord after PROG treatment. Taken together, these results indicate that PROG is effective in reducing the severity of chronic EAE and, consequently, may have potential with respect to MS treatment.

UI MeSH Term Description Entries
D008297 Male Males
D011374 Progesterone The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS. Pregnenedione,Progesterone, (13 alpha,17 alpha)-(+-)-Isomer,Progesterone, (17 alpha)-Isomer,Progesterone, (9 beta,10 alpha)-Isomer
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004681 Encephalomyelitis, Autoimmune, Experimental An experimental animal model for central nervous system demyelinating disease. Inoculation with a white matter emulsion combined with FREUND'S ADJUVANT, myelin basic protein, or purified central myelin triggers a T cell-mediated immune response directed towards central myelin. The pathologic features are similar to MULTIPLE SCLEROSIS, including perivascular and periventricular foci of inflammation and demyelination. Subpial demyelination underlying meningeal infiltrations also occurs, which is also a feature of ENCEPHALOMYELITIS, ACUTE DISSEMINATED. Passive immunization with T-cells from an afflicted animal to a normal animal also induces this condition. (From Immunol Res 1998;17(1-2):217-27; Raine CS, Textbook of Neuropathology, 2nd ed, p604-5) Autoimmune Encephalomyelitis, Experimental,Encephalomyelitis, Allergic,Encephalomyelitis, Experimental Autoimmune,Allergic Encephalomyelitis,Allergic Encephalomyelitis, Experimental,Autoimmune Experimental Encephalomyelitis,Experimental Allergic Encephalomyelitis,Experimental Autoimmune Encephalomyelitis,Encephalomyelitis, Autoimmune Experimental,Encephalomyelitis, Experimental Allergic,Experimental Allergic Encephalomyelitides,Experimental Encephalomyelitis, Autoimmune
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013116 Spinal Cord A cylindrical column of tissue that lies within the vertebral canal. It is composed of WHITE MATTER and GRAY MATTER. Coccygeal Cord,Conus Medullaris,Conus Terminalis,Lumbar Cord,Medulla Spinalis,Myelon,Sacral Cord,Thoracic Cord,Coccygeal Cords,Conus Medullari,Conus Terminali,Cord, Coccygeal,Cord, Lumbar,Cord, Sacral,Cord, Spinal,Cord, Thoracic,Cords, Coccygeal,Cords, Lumbar,Cords, Sacral,Cords, Spinal,Cords, Thoracic,Lumbar Cords,Medulla Spinali,Medullari, Conus,Medullaris, Conus,Myelons,Sacral Cords,Spinal Cords,Spinali, Medulla,Spinalis, Medulla,Terminali, Conus,Terminalis, Conus,Thoracic Cords
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D018696 Neuroprotective Agents Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. Neuroprotectant,Neuroprotective Agent,Neuroprotective Drug,Neuroprotectants,Neuroprotective Drugs,Neuroprotective Effect,Neuroprotective Effects,Agent, Neuroprotective,Agents, Neuroprotective,Drug, Neuroprotective,Drugs, Neuroprotective,Effect, Neuroprotective,Effects, Neuroprotective

Related Publications

S Giatti, and D Caruso, and M Boraso, and F Abbiati, and E Ballarini, and D Calabrese, and M Pesaresi, and R Rigolio, and M Santos-Galindo, and B Viviani, and G Cavaletti, and L M Garcia-Segura, and R C Melcangi
March 2024, Nature neuroscience,
S Giatti, and D Caruso, and M Boraso, and F Abbiati, and E Ballarini, and D Calabrese, and M Pesaresi, and R Rigolio, and M Santos-Galindo, and B Viviani, and G Cavaletti, and L M Garcia-Segura, and R C Melcangi
October 2018, European review for medical and pharmacological sciences,
S Giatti, and D Caruso, and M Boraso, and F Abbiati, and E Ballarini, and D Calabrese, and M Pesaresi, and R Rigolio, and M Santos-Galindo, and B Viviani, and G Cavaletti, and L M Garcia-Segura, and R C Melcangi
November 2014, Journal of neuroimmunology,
S Giatti, and D Caruso, and M Boraso, and F Abbiati, and E Ballarini, and D Calabrese, and M Pesaresi, and R Rigolio, and M Santos-Galindo, and B Viviani, and G Cavaletti, and L M Garcia-Segura, and R C Melcangi
October 2019, Neurochemistry international,
S Giatti, and D Caruso, and M Boraso, and F Abbiati, and E Ballarini, and D Calabrese, and M Pesaresi, and R Rigolio, and M Santos-Galindo, and B Viviani, and G Cavaletti, and L M Garcia-Segura, and R C Melcangi
October 2017, Journal of neuroinflammation,
S Giatti, and D Caruso, and M Boraso, and F Abbiati, and E Ballarini, and D Calabrese, and M Pesaresi, and R Rigolio, and M Santos-Galindo, and B Viviani, and G Cavaletti, and L M Garcia-Segura, and R C Melcangi
May 2021, Immunology letters,
S Giatti, and D Caruso, and M Boraso, and F Abbiati, and E Ballarini, and D Calabrese, and M Pesaresi, and R Rigolio, and M Santos-Galindo, and B Viviani, and G Cavaletti, and L M Garcia-Segura, and R C Melcangi
August 2009, Brain research,
S Giatti, and D Caruso, and M Boraso, and F Abbiati, and E Ballarini, and D Calabrese, and M Pesaresi, and R Rigolio, and M Santos-Galindo, and B Viviani, and G Cavaletti, and L M Garcia-Segura, and R C Melcangi
July 2011, Immunology,
S Giatti, and D Caruso, and M Boraso, and F Abbiati, and E Ballarini, and D Calabrese, and M Pesaresi, and R Rigolio, and M Santos-Galindo, and B Viviani, and G Cavaletti, and L M Garcia-Segura, and R C Melcangi
March 2023, International immunopharmacology,
S Giatti, and D Caruso, and M Boraso, and F Abbiati, and E Ballarini, and D Calabrese, and M Pesaresi, and R Rigolio, and M Santos-Galindo, and B Viviani, and G Cavaletti, and L M Garcia-Segura, and R C Melcangi
February 2010, Journal of neuroimmunology,
Copied contents to your clipboard!